|会社名||Illumina Inc （イルミナ）|
|分野（sector）||Capital Goods 資本財（工業製品）|
|産業（industry）||Biotechnology: Laboratory Analytical Instruments|
|業種||先端医療機器_テクノロジ― 医療関連（Health Care）|
|概要||事業概要 イルミナ(Illumina Inc.)は遺伝子解析用シーケンシングおよびアレイベースのソリューションを提供する。同社は2つの事業を運営する。Core Illuminaと連結変動持分事業体（VIE）事業は、GRAIL Inc. (GRAIL)とHelix Holdings I LLC (Helix)の運営を含む。Core Illuminaは核心事業を含む。その製品とサービスは、研究、臨床及び応用市場で顧客にサービスを提供し、多様なゲノムソリューションの採用を可能にする。同社の統合システム、消耗品及び分析ツールのポートフォリオは、ゲノムの複雑さ、価格ポイント、およびスループットに対応し、顧客が研究または臨床上の課題に対してソリューションを選択できるようにする。同社は、非侵襲的な出生前検査（NIPT）、着床前の遺伝的スクリーニングと診断、並びに新生児および遺伝的健康検査を含む、生殖医療ソリューションを提供している。 イルミナは、遺伝学および健康についての理解を推進する為の統合的なソリュ―ションのプロバイダ―。遺伝的変異および遺伝子機能の大規模解析を行うための包括的なライフサイエンスツ―ルとシステムの開発、製造、販売を行う。顧客は世界中のさまざまな学術機関、政府機関、製薬企業、バイオテクノロジ―企業、および他の主要な機関を含む。 Illumina is improving human health by unlocking the power of the genome. Its focus on innovation has established it as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. The Company products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.|
|本社所在地||5200 Illumina Way San Diego CA 92122 USA|
|代表者氏名||Jay T. Flatley ジェイ・T・フラットリー|
|代表者役職名||Executive Chairman of the Board 取締役会長|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the six months ended 01 July 2018 Illumina Inc. revenues increased 28% to $1.61B. Net income decreased 16% to $417M. Revenues reflect Consolidated VIEs segment increase of 100% to $6M. Basic Earnings per Share excluding Extraordinary Items decreased from $3.39 to $2.84.|
The Market Continues To Underprice Illumina''s Stock And Its Genomics Leadership 2023/06/01 08:54:23 Seeking Alpha
Illumina is undervalued by 23% according to a discounted cash flow analysis, with a fair value of $253.94. Read why ILMN stock is a Buy.
Illumina CEO survived Icahn’s challenge by more than 2-to-1 margin By Reuters 2023/05/31 01:08:28 Investor Daily Updates
2/2 © Reuters. FILE PHOTO: The offices of gene sequencing company Illumina Inc are shown in San Diego, California January 11, 2016. REUTERS/Mike Blake 2/2 By Svea Herbst-Bayliss NEW YORK (Reuters) – Illumina Inc (NASDAQ:) CEO Francis deSouza survived a challenge to his board seat from activist investor Carl Icahn last week by securing more […] The post Illumina CEO survived Icahn’s challenge by more than 2-to-1 margin By Reuters first appeared on Forex Trader Hub .
Illumina CEO survived Icahn''s challenge by more than 2-to-1 margin 2023/05/30 22:46:39 Investing.com
Illumina CEO survived Icahn’s challenge by more than 2-to-1 margin 2023/05/30 22:36:39 Financial Post
NEW YORK — Illumina Inc CEO Francis deSouza survived a challenge to his board seat from activist investor Carl Icahn last week by securing more than twice the shareholder votes than the number his challenger received, the company said in a filing on Tuesday. While the outcome of the vote was known, the tally had […]
Insider trades & hedge fund moves: Carl Icahn tosses out Illumina chair 2023/05/30 07:42:05 Investing.com
Tracking COVID-19 With Dust at the Ohio State University 2022/10/18 17:10:00 Accesswire
NORTHAMPTON, MA / ACCESSWIRE / October 18, 2022 / When COVID-19 hit, most of The Ohio State University-home of the Buckeyes in the state capital of Columbus-shut down. But the Applied Microbiology Services Laboratory (ASML) within its Infectious Diseases Institute (IDI) stayed open. "The Buckeyes are amazing students," says Seth Faith, who serves as the executive director for the Center of Microbiome Science and strategic alliance officer for IDI, but also supervises the lab. "A lot of them are hungry and passionate. At least one individual working in the lab had family in Wuhan, China, and they hadn''t seen their family for two years. They wanted to be a part of solving this pandemic." Over the next two years or so, AMSL employed 88 lab workers at various times, who administered more than 850,000 PCR diagnostic tests for COVID-19, with an average turnaround time of 8.75 hours. Meanwhile, an OSU professor named Karen Dannemiller had been going into homes and businesses looking for toxic chemicals in the built environment.
Illumina, GenoScreen collaborate on genomic testing for drug-resistant TB 2022/10/18 10:53:32 Seeking Alpha
Illumina (ILMN) and GenoScreen are collaborating to expand access to genomic testing for multidrug-resistant ((MDR)) tuberculosis ((TB)) in an effort to end the disease…
Illumina and GenoScreen Partner to Expand Access to Genomic Testing for Multidrug-Resistant Tuberculosis 2022/10/18 10:00:00 PR Newswire
Transformative alliance will help advance the World Health Organization''s strategy to end the global TB epidemic by 2035 SAN DIEGO, Oct. 18, 2022 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and GenoScreen, an innovative…
Boosting STEM Education in Bangladesh 2022/10/17 13:10:00 Accesswire
NORTHAMPTON, MA / ACCESSWIRE / October 17, 2022 / Illumina and the Illumina Corporate Foundation have provided a grant to the Child Health Research Foundation (CHRF), a Bangladeshi nonprofit that promotes public health and STEM education. The grant, worth over $300,000, includes cash and in-kind product. The grant will support CHRF''s Building Scientists for Bangladesh program , which will introduce young women in under-resourced communities around the country to science and provide hands-on genomic training for university students and early career professionals. Bangladesh faces a multifaceted problem: Disease burden is high, and access and exposure to STEM education and the benefits and practice of science remain low. To complicate matters further, Bangladeshi universities are experiencing a significant decline in STEM enrollment, particularly among women. CHRF director Senjuti Saha, PhD, and her team hope to counteract this discouraging trend. "We believe that everyone across the world should have equal access to the practice and benefits of science and that if more young women completing high school can see themselves as scientists addressing problems in their communities, they will be encouraged to pursue STEM," says Saha, who is spearheading the education program. "To make science more relatable to their everyday lives-not limited to theories they read about in textbooks-our researchers will take science to high schools across the country, especially in rural communities, and perform easy-to-do experiments to engage students and teachers." The Mission CHRF has been working in Bangladesh since the 1980s because pediatric infections were causing far too many preventable deaths.
In Our DNA: Suzanne Rohrback, Senior Staff Bioinformatics Scientist at Illumina 2022/10/14 13:45:00 Accesswire
NORTHAMPTON, MA / ACCESSWIRE / October 14, 2022 / Illumina: As a scientist on Illumina''s Assay Research team in San Diego, Suzanne Rohrback works with colleagues to come up with new ways next-generation sequencing (NGS) can maximize insights from a sample-such as cells from a tumor or a tube of blood-extracting as much information about it as possible, as efficiently as possible. Specifically, Rohrback''s role is in bioinformatics; she works closely with her coworkers who perform experiments, turning their hypotheses into code and graphs that build a deep understanding of the system at hand. As she puts it: "I''m a data detective! I''m always asking, ‘What''s different between these samples and why did it change?'' Answering this teaches us how biology works and identifies warning signals that could help doctors and scientists understand, diagnose, or treat disease." Rohrback was an early member of the team that developed the Illumina COVIDSeq™ Test , a high-throughput, sequencing-based, in vitro diagnostic workflow that enables the detection of SARS-CoV-2. "Everything went from zero to 60 in an instant," she says. "I''ve never been so hyper-focused or felt so purposeful and connected to so many coworkers across the globe-many of whom I''d never met.
Illumina Whale Trades Spotted 2022/07/08 21:01:03 Benzinga
A whale with a lot of money to spend has taken a noticeably bearish stance on Illumina . Looking at options history for Illumina (NASDAQ: ILMN ) we detected 11 strange trades. If we consider the specifics of each trade, it is accurate to state that 36% of the investors opened trades with bullish expectations and 63% with bearish. From the overall spotted trades, 4 are puts, for a total amount of $181,215 and 7, calls, for a total amount of $471,633. What''s The Price Target? Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $185.0 to $260.0 … Full story available on Benzinga.com
The 3 Best Retirement Stocks for Gen-Z Investors 2022/07/07 14:52:01 InvestorPlace
“Time is on my side, yes it is.” If you’re of a certain age the message sings to you. But the stock market doesn’t heed those words, and truly strong opportunities to boost long-term returns are fleeting. Moreover and pairing the two, right now Wall Street is offering the best retirement stocks for Gen-Z investors to buy at “remember the good ol’ days” style share prices. Retirement? For those born between 1997 and 2012 it’s the last thing you’re thinking or likely preparing for. The fact is you’re young enough to feel invincible. And to be fair, living in the moment and owning the words made famous by The Rolling Stones probably feels right. But whether you’re just out of college or still in grade school, a bear market that’s the other and older generations’ problem is a dynamic real-time chance for younger people in Gen-Z to take notice and profit from. 7 Best Bargain Stocks to Buy in July 2022 Today, decide to start controlling your future with the compounding of money and three of the best retirement stocks for Gen-Z investors now offered at extremely-advantaged prices.
3 Biotech Stocks to Sell Now 2022/07/05 18:16:38 InvestorPlace
Biotech stocks have been brought low over the past 18 months. Both the iShares Biotechnology ETF (NASDAQ: IBB ) and S&P Biotech ETF (NYSEARCA: XBI ), Wall Street’s two most popular funds that track the industry, dropped 33% and 57% since peaking last February. But the losses were worse two weeks ago. Many biotechs rallied back, and both ETFs are sporting double bottom formations. Unfortunately, some components still have broken trends and remain vulnerable to further downside. I scoured the top holdings of IBB and XBI to discover the worst charts. That means their trends remain bearish and overhead resistance will threaten recovery attempts. At a minimum, anyone bottom fishing should avoid these companies. Beyond that, they are all top biotech stocks to sell before more significant losses arrive. For those with the good fortune of not owning these, consider them all quality picks for bear trades if you want to profit from their pain. Let me show you how. Ticker Company Price ILMN Ilumina $190.75 BIIB Biogen $211.07 IQV Iqvia Holdings $212.57 Biotech Stocks: Ilumina (ILMN) Source: The thinkorswim® platform from TD Ameritrade Drawdown Depth: -66% Illumina (NASDAQ: ILMN ) provides sequencing and array-based solutions for genetic and genomic analysis.
7 Beaten-Down S&P 500 Stocks to Buy Before They Rebound 2022/06/30 10:00:35 InvestorPlace
S&P 500 stocks have been a mixed bag at best this year. During the week of June 21, I think the market began to accept the idea that a ” soft landing” by the economy is much more likely than a “hard landing.” Of course, the market rallied during the week. As further evidence of the Street’s renewed optimism, Goldman Sachs economist Jan Hatzius, speaking on Bloomberg TV o n June 24, said that any recession would probably be “on the shallow end.” Even more bullish was RBC Capital Managing Director Gerard Cassidy, who told Bloomberg TV on June 24 that “as long as the job market stays strong, (U.S.) consumers will be in good shape.” 7 REITs to Buy for a Bear Market With the Street realizing that the economy is not going to crash, I believe that there are many good S&P 500 stocks to buy. Meanwhile, as Bloomberg TV’s Lisa Abramowicz pointed out on June 24, many market participants now think that Fed Chairman Jerome Powell will be less “hawkish” on inflation than the Street has generally believed in recent months.
Here''s How Much You Would Have Made Owning Illumina Stock In The Last 15 Years 2022/06/29 18:13:56 Benzinga
Illumina (NASDAQ: ILMN ) has outperformed the market over the past 15 years by 9.39% on an annualized basis producing an average annual return of 15.68%. Currently, Illumina has a market capitalization of $29.25 billion. Buying $1000 In ILMN: If an … Full story available on Benzinga.com